You are here:

elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg, tenofovir disoproxil (as fumarate) 245mg film coated tablet (Stribild®)

Advice

following a full submission:

elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil (as fumarate) film coated tablet (Stribild®) is accepted for use within NHS Scotland.

Indication under review: treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.

Stribild® was at least as effective as two other recommended antiretroviral regimens in treatment-naïve HIV-1 infected patients.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of Stribild®. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
 

Drug Details

Drug Name: elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg, tenofovir disoproxil (as fumarate) 245mg film coated tablet (Stribild®)
SMC Drug ID: 887/13
Manufacturer: Gilead Sciences Ltd
Indication: For treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 August 2013

Back